Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Choi, Ji Won | - |
dc.contributor.author | Shin, Su Jeong | - |
dc.contributor.author | Kim, Hyeon Ji | - |
dc.contributor.author | Park, Jong-Hyun | - |
dc.contributor.author | Kim, Hyeon Jeong | - |
dc.contributor.author | Lee, Elijah Hwejin | - |
dc.contributor.author | Pae, Ae Nim | - |
dc.contributor.author | Bahn, Yong Sun | - |
dc.contributor.author | Park, Ki Duk | - |
dc.date.accessioned | 2024-01-19T19:34:15Z | - |
dc.date.available | 2024-01-19T19:34:15Z | - |
dc.date.created | 2021-09-02 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.issn | 1948-5875 | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/119829 | - |
dc.description.abstract | The main pathway responsible for cellular regulation against oxidative stress is nuclear factor E2-related factor-2 (Nrf2) signaling. We previously synthesized and reported a novel vinyl sulfone (1) as an Nrf2 activator with therapeutic potential for Parkinson's disease (PD). In this study, we changed the vinyl sulfone to vinyl sulfonamide or vinyl sulfonate to improve Nrf2 activating efficacy. We observed that the introduction of vinyl sulfonamide led to a reduction of the effects on Nrf2 activation, whereas vinyl sulfonate compounds exhibited superior activity compared to the vinyl sulfone compounds. Among the vinyl sulfonates, 3c exhibited 6.9- and 83.S-fold higher effects on Nrf2 activation than the corresponding vinyl sulfone (1) and vinyl sulfonamide (2c), respectively. Compound 3c was confirmed to induce expression of the Nrf2-dependent antioxidant enzymes at the protein level in cells. In addition, 3c mitigated PD-associated behavioral deficits by protecting DAergic neurons in the MPTP-induced mouse model of PD. | - |
dc.language | English | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | TRANSCRIPTION FACTOR NRF2 | - |
dc.subject | PARKINSONS-DISEASE | - |
dc.subject | DOPAMINERGIC-NEURONS | - |
dc.subject | OXIDATIVE STRESS | - |
dc.subject | MOUSE MODEL | - |
dc.subject | DEFICIENCY | - |
dc.subject | MECHANISMS | - |
dc.subject | PARAMETERS | - |
dc.subject | DECLINE | - |
dc.subject | PATHWAY | - |
dc.title | Antioxidant, Anti-inflammatory, and Neuroprotective Effects of Novel Vinyl Sulfonate Compounds as Nrf2 Activator | - |
dc.type | Article | - |
dc.identifier.doi | 10.1021/acsmedchemlett.9b00163 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | ACS MEDICINAL CHEMISTRY LETTERS, v.10, no.7, pp.1061 - 1067 | - |
dc.citation.title | ACS MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 10 | - |
dc.citation.number | 7 | - |
dc.citation.startPage | 1061 | - |
dc.citation.endPage | 1067 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000475543200010 | - |
dc.identifier.scopusid | 2-s2.0-85067409345 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | TRANSCRIPTION FACTOR NRF2 | - |
dc.subject.keywordPlus | PARKINSONS-DISEASE | - |
dc.subject.keywordPlus | DOPAMINERGIC-NEURONS | - |
dc.subject.keywordPlus | OXIDATIVE STRESS | - |
dc.subject.keywordPlus | MOUSE MODEL | - |
dc.subject.keywordPlus | DEFICIENCY | - |
dc.subject.keywordPlus | MECHANISMS | - |
dc.subject.keywordPlus | PARAMETERS | - |
dc.subject.keywordPlus | DECLINE | - |
dc.subject.keywordPlus | PATHWAY | - |
dc.subject.keywordAuthor | Parkinson&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | antioxidant | - |
dc.subject.keywordAuthor | anti-inflammatory | - |
dc.subject.keywordAuthor | Nrf2/Keapl pathway | - |
dc.subject.keywordAuthor | MPTP mouse model | - |
dc.subject.keywordAuthor | vinyl sulfone | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.